Aclipse Therapeutics to Collaborate with Mayo Clinic on Phase 2 Clinical Development of M107 for the Treatment of Gastroparesis
Aclipse Therapeutics LLC (“Aclipse” or “the Company”) today announced that it has entered into a clinical collaboration and Know-How Agreement with Mayo Clinic for the Phase 2 clinical development of M107, the Company’s novel small molecule drug candidate being advanced as a potential disease modifying treatment for gastroparesis (i.e., stomach paralysis). The collaboration leverages the combined scientific and clinical expertise of both organizations to target macrophage related inflammation and seeks to address the biological cause of gastroparesis, a chronic and debilitating disease affecting stomach nerves and muscles resulting in stomach paralysis and delayed stomach emptying.
Aclipse Therapeutics Selected to Present M102 ALS Clinical Development Program at Prestigious ALS and Motor Neurone Disease Symposia
Aclipse Therapeutics LLC (“Aclipse” or “the Company”) today announced that its M102 drug development program has been selected for presentations at the premier amyotrophic lateral sclerosis (ALS) and motor neurone disease (MND) symposia this fall.
